Key result
Valsartan suppresses urinary catecholamines and arrhythmias in a single hypertensive patient.
Why the study?
Does valsartan reduce urinary catecholamines and arrhythmias in a hypertensive patient?
Case Report (n=1)
Does valsartan reduce urinary catecholamines and arrhythmias in a hypertensive patient?
Valsartan successfully suppressed elevated urinary catecholamines and frequent premature contractions in a hypertensive patient.
Answers are grounded in this paper and cite their sources.
Does not support practice change for hypertensive arrhythmias; hypothesis-generating case report requiring prospective validation.
We report a case of a 64-year-old woman with hypertension. She had dizziness and palpitation without heart failure although she was taking amlodipine. Urine levels of epinephrine and norepinephrine were high and both atrial and ventricular premature contraction were frequently seen. Valsartan, angiotensin II type 1 receptor antagonist, decreased these catecholamine levels and suppressed arrhythmias in the present case without the use of other drugs such as beta-blockers or anti-arrhythmic agents. In conclusion, valsartan is one option that can be used to prevent arrhythmias as well as to control blood pressure in hypertensive patients.
No takes yet. Share an insight, caveat, or question.
Hayashida et al. (2005) conducted a case report in Hypertension and arrhythmias (n=1). Valsartan was evaluated on Urinary catecholamines and arrhythmias. Valsartan suppressed an increase in urinary catecholamines and arrhythmias in a patient with hypertension.
Synapse has enriched 10 related papers. Consider them for comparative context: